coplug
    Back to PCN explorer
    PCN reports · Core20PLUS5

    Bramhall And Cheadle Hulme PCN Ltd, Stockport (LAD) · Health Inequalities Profile

    PCN U37388 · NHS Greater Manchester Integrated Care Board · 5 GP practices

    Read the report

    This report is generated by Coplug's Healthcare Agent. Log in to ask further questions of it, add the spatial context, or create new enquiries to better understand and improve your Neighbourhood's Health

    01 / 15

    Board summary

    Key figures

    59,069

    Registered population

    56.8% aged 18–64

    22.8%

    Aged 65+

    ICB 14.9% · England 17.9%

    4.7%

    In IMD quintile 1

    ICB 40.7% · England 21.0%

    ~2,602

    Core20 residents (est.)

    Resident basis; registered basis ~2,982 · see page 3

    9,337

    Hypertension register

    +3.57% in 3 yrs · England +5.60%

    465

    SMI register

    13.9% of Stockport (LAD)'s

    810

    COPD register

    Reviews -8.45% in 3 yrs

    Forecast to 2030

    10,160

    Hypertension patients, 2030

    +823 on today

    65.9%

    QRISK ≥20% on statins, 2030

    +2.18pp over 3 yrs

    6.4%

    Cancer prevalence, 2030

    England 4.5%

    Three things the board should see

    58.9%
    Asthma review coverage fell below England.

    Annual asthma reviews fell 8.0% over 2023 to 2025 to 58.9% (England 65.7%, +4.4%), leaving an estimated 1,528 unreviewed patients.

    20.8%
    Deprivation and access pressure concentrate in one practice.

    Bramhall & Shaw Heath Medical Group holds a 20.8% Core20 share (2,736 estimated patients), alongside 46.7% phone contact ease and 31.9% QOF vaccination achievement.

    91.7%
    Strong SMI physical checks and hypertension control.

    SMI blood pressure checks rose +10.7 pp over 2023 to 2025 to 91.7% (England 83.4%), while hypertension treatment to target reached 75.6% (England 70.3%).

    Sources & context

    PCN and practice-level primary care data; ICB and provider context on page 8

    Powered by Coplug · Page 1 of 15
    02 / 15

    Population, age and ethnicity

    Aged 65+ patients account for 22.8% of the list, above borough and England

    Bramhall and Cheadle Hulme PCN serves 59,069 registered patients. Patients aged 65+ represent 22.8% of the list (13,456 patients), above Stockport (LAD) (19.7%), NHS Greater Manchester Integrated Care Board (14.9%), and England (17.9%). Working-age adults aged 18-64 comprise 56.8% (33,569) and children aged 0-17 make up 20.4% (12,044). Recorded Roma residents represent 0.1% and Gypsy or Irish Traveller 0.0%. Projected population growth to 2030 is 0.6% (Stockport (LAD) 1.1%, NHS Greater Manchester Integrated Care Board 1.6%, England 2.3%), though projection methodology is unverified.

    Age profile

    0–1720.4%
    18–6456.8%
    65+22.8%

    65+: ICB 14.9%, England 17.9%

    Older people · falls rows are Stockport (LAD) local-authority (LA) data, not PCN

    MeasureLocalNorth WestEnglandPeriod
    Falls admissions, 65+, per 100,000 (Stockport LA)2,0722,0711,9582024/25
    Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN)85.4%82.9%81.9%2024/25
    Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN)59.0%56.6%57.4%2024/25
    Falls admissions, 65 to 79, per 100,000 (Stockport LA)9191,0219552024/25
    Falls deaths, all ages, per 100,000 (Stockport LA)23.718.214.82022‑24
    Sources & context

    Census 2021; Fingertips falls and diabetes. Falls are local-authority data. Ethnic minority = 100% minus White

    Powered by Coplug · Page 2 of 15
    03 / 15

    Deprivation and Core20

    Core20 deprivation is 4.7% overall but concentrates sharply at one practice

    Average IMD decile is 8.2 (Stockport (LAD) 6.4, NHS Greater Manchester Integrated Care Board 4.5, England 5.5). PCN Core20 share is 4.7% (Stockport (LAD) 16.1%, NHS Greater Manchester Integrated Care Board 40.7%, England 21.0%), though weighted practice share is 5.0% (a 0.33 percentage point difference; resident estimate 2,602). Across a 20.8 pp practice spread, Core20 patients concentrate at Bramhall & Shaw Heath Medical Group (20.8%, 2,736 estimated patients) and Hulme Hall Medical Group (2.4%, 246), with 0.0% across the other three practices. Proactive Core20 support is most efficiently directed to.

    % of patients in IMD quintile 1, by practice

    Dashed line: England 21.0% · right column: Core20 patients, registered basis

    Bramhall & Shaw20.8% · 2,736 patients
    Hulme Hall2.4% · 246 patients
    Cheadle Hulme0.0% · 0 patients
    Bramhall0.0% · 0 patients
    Village0.0% · 0 patients
    Sources & context

    Deprivation: Index of Multiple Deprivation, applied to registered patients

    Powered by Coplug · Page 3 of 15
    04 / 15

    PLUS groups and inclusion health

    PLUS groups and inclusion health

    465

    SMI register

    0.78% recorded prevalence

    273

    Learning disability register

    0.46% recorded prevalence

    26

    Care homes, 1,272 beds

    In the PCN catchment

    9.5%

    Provide unpaid care

    Stockport (LAD), Census 2021

    The PCN records 465 patients on the severe mental illness register (0.8% vs England 1.0%, Stockport (LAD) 1.0%, NHS Greater Manchester Integrated Care Board 1.1%) and 273 on the learning disability register (0.5% vs England 0.6%, Stockport (LAD) 0.6%, NHS Greater Manchester Integrated Care Board 0.6%), alongside 26 catchment care homes holding 1,272 beds. Crude register differences do not establish under-detection, though monitoring annual health check completion can support care.

    Severe mental illness: physical health checks

    Recorded SMI blood pressure checks reached 91.7% (England 83.4%) and BMI recording 92.0% (England 82.1%). Missing check elements cannot imply full completion, and practice rates fall to 75.0% at The Village Surgery.

    Sources & context

    QOF registers; Census 2021 carers; care homes and homelessness as supplied. Carers and homelessness are local-authority data

    Powered by Coplug · Page 4 of 15
    05 / 15

    Clinical focus: hypertension and lipids

    Clinical focus: hypertension and lipids

    9,337

    Hypertension register

    +3.57%

    Register growth, 3 yrs

    Stockport (LAD) +4.99% · England +5.60%

    −0.37pp

    BP control, under 80

    ≤140/90 · −0.21pp aged 80+

    +823

    More patients by 2030

    Forecast 10,160 (16.87%)

    Hypertension case-finding and control

    Recorded hypertension prevalence is 15.7% (9,337 patients), below Stockport (LAD) (16.2%) but above England (15.2%) and NHS Greater Manchester Integrated Care Board (14.4%). Blood pressure monitoring reach is strong at 92.5% (England 90.0%), and treatment to target is 75.6% (England 70.3%; 72.6% for patients aged under 80 and 83.4% for those aged 80+). However, over 2023 to 2025, register growth of +3.6% trailed Stockport (LAD) (+5.0%) and England (+5.6%), while control under 80 fell 0.5% (England +3.2%). Hypertension register growth and under-80 control trail national progress despite strong current achievement, so prioritising opportunistic blood pressure case-finding and titration reviews could protect control across an older population.

    Lipids and statins

    For patients with QRISK ≥ 20%, lipid-lowering therapy uptake is 61.3%, trailing Stockport (LAD) (64.8%), England (63.6%), and NHS Greater Manchester Integrated Care Board (67.0%). Fewer at-risk patients receive lipid-lowering therapy than England and ICB rates imply, so a systematic recall audit of eligible patients with QRISK ≥ 20% is the priority.

    MeasureItemsCost / itemICBEnglandAnnual spend
    Lipid-modifying, 202694,554£2.50£1.94£1.86£236,385
    Cardiovascular (all), 2025131,719£4.64£3.15£3.33£611,176

    In 2026, lipid-modifying drugs cost £2.50 per item across 94,554 items, above Stockport (LAD) (£1.99), NHS Greater Manchester Integrated Care Board (£1.94), and England (£1.86), spending £60,515 more than at England's unit cost. Higher unit costs for lipid-modifying items than comparators indicate an opportunity to review prescribing choices and formulary alignment across practices.

    Sources & context

    QOF hypertension register and BP control indicators; prescribing items and cost as supplied

    Powered by Coplug · Page 5 of 15
    06 / 15

    Clinical focus: respiratory, cancer register and children

    Clinical focus: respiratory, cancer register and children

    Respiratory

    −7.98%

    Asthma reviews, PCN 3-yr % change

    +4.44%

    Asthma reviews, England 3-yr % change

    +0.49%

    Asthma prevalence, PCN 3-yr % change

    Asthma reviews fell 8.0% over 2023 to 2025 to 58.9% (Stockport (LAD) 63.4%, NHS Greater Manchester Integrated Care Board 66.2%, England 65.7%, England +4.4%), leaving an estimated scale gap of 1,528 unreviewed patients across the 3,718 register. COPD reviews fell 8.4% to 69.8% (Stockport (LAD) 76.4%, England 76.4%, England +2.8%), while the 810 COPD register fell 4.7% over 2023 to 2025 (England +2.6%; prevalence 1.4% vs England 1.9%). Slower respiratory reviews and register decline may indicate recall pressures.

    Cancer register and children's immunisation

    Cancer register prevalence is 5.0% (2,936 patients), above England (3.8%). In Q1 2025/26, 12-month 6-in-1 coverage was 88.5%, below the 95.0% target by 6.5 pp (England 91.0%), whereas 24-month course completion was 99.2%. At age 5, 4-in-1 booster coverage was 92.5% (below the 95.0% target by 2.5 pp) and MMR dose 2 coverage reached 95.0%.

    Dashed line: 95% national coverage target · solid tick: England

    6-in-1 at 12 months88.5%

    England 91.0%

    6-in-1 complete primary course at 24 months99.2%

    England 92.2%

    MMR dose 1 at 24 months97.5%

    England 88.3%

    MMR dose 2 at age 595.0%

    England 82.8%

    4-in-1 pre-school booster at age 592.5%

    England 80.9%

    Sources & context

    QOF registers and review indicators; childhood immunisation coverage as supplied

    Powered by Coplug · Page 6 of 15
    07 / 15

    Early cancer diagnosis

    Early cancer diagnosis

    55.6%

    Greater Manchester ICB, stage 1–2

    55.3%

    England, 2022

    75%

    National ambition by 2028

    ~2,270

    Extra early-stage cases a year to reach the ambition

    Stage 1–2 share by cancer type, 2022Greater Manchester ICBEnglandNo usable stageStaged cancers
    Lung40.4%33.8%15%2,193
    Prostate61.7%53.2%14%1,788
    Breast82.5%85.4%19%1,758
    Bowel46.3%47.0%19%1,427
    Skin cancer84.5%87.8%27%580

    In 2022, 55.6% of staged cancers in NHS Greater Manchester ICB were diagnosed at stage 1 or 2 (6,491 of 11,679 known-stage cases; England 55.3%), a distance of -19.4 pp to the 75.0% national ambition by 2028 and requiring about 2,270 additional early-stage cases. Of 16,492 registered cancers, 70.8% had a known stage; staging reflects ICB system data, not PCN performance. At PCN level, recorded cancer prevalence is 5.0% (2,936 patients; 3-year change +13.6% vs England +9.0%). Cervical screening (25-49) is 75.0% (England 66.8%), while Bramhall & Shaw Heath Medical Group records 68.2%.

    Sources & context

    Stage at diagnosis: National Disease Registration Service

    Powered by Coplug · Page 7 of 15
    08 / 15

    Cancer waits, diagnostics and community services

    Cancer waits, diagnostics and community services

    Cancer waits and diagnostics, Jul 2026 (provisional)

    In Jul 2026 (provisional), Stockport NHS Foundation Trust achieved 83.2% on the 28-day faster diagnosis standard (East Cheshire NHS Trust 81.1%, Manchester University NHS Foundation Trust 80.1%, NHS Greater Manchester Integrated Care Board 79.5%, England 79.3%; 75.0% standard) and 97.4% on the 31-day standard (England 92.5%). On the 62-day standard, it reached 74.7% (distance of -10.3 pp to the 85.0% standard; ICB 75.7%, England 71.2%). Diagnostic 6+ week waits were 1.4% for MRI and 2.9% for CT, but 67.7% for audiology. Provider waiting times reflect trust activity, not PCN performance.

    Pathways within standard (%)StockportManchesterEast CheshireGreater Manchester ICBEngland
    28-day faster diagnosis (75%)83.2180.0681.0879.5379.32
    31-day treatment (96%)97.3992.5496.3096.4992.50
    62-day referral to treatment (85%)74.6772.8553.4175.7371.16
    Diagnostic waits over 6 weeks (%)StockportManchesterEast CheshireEngland
    MRI1.4111.6826.6221.40
    CT2.9314.6611.499.92
    Echocardiography17.464.9126.2428.48
    Colonoscopy5.534.5110.8530.83
    Gastroscopy5.3129.3510.2529.02
    All 15 DM01 tests14.088.9816.1723.14
    Community services activityStockport residentsGreater Manchester ICB
    Care contacts57,085573,310
    Referrals10,69094,470
    Patients with a contact16,950183,535

    Community services (residents of Stockport), Jun 2026 (provisional). In Jun 2026 (provisional), community services recorded 57,085 contacts with Stockport residents, with 34,585 contacts among adults aged 65+, representing 60.6% of borough contacts. These figures describe wider local authority resident activity and were not captured at PCN level.

    Sources & context

    Waits and diagnostics: NHS England monthly statistics · ICB and provider data, not PCN

    Powered by Coplug · Page 8 of 15
    09 / 15

    Practice variation and patient experience

    Phone access and vaccination vary widely across practices despite strong overall clinical achievement

    Overall QOF achievement for 2025/26 spans from 92.2% at Bramhall & Shaw Heath Medical Group to 100.0% at Bramhall Health Centre. Clinical-domain achievement reached 100.0% at both practices. In vaccination and immunisation, achievement showed a 68.1 pp range, from 31.9% at Bramhall & Shaw Heath Medical Group to 100.0% at Bramhall Health Centre.

    GP Patient Survey by practice

    PracticeResponses% in IMD Q1Phone easyRequest led to apptOverall good
    Village1000.078.0%75.2%94.5%
    Hulme Hall1182.458.1%71.3%92.7%
    Cheadle Hulme1130.053.4%76.7%90.9%
    Bramhall1130.063.0%71.5%88.8%
    Bramhall & Shaw9520.846.7%71.5%70.6%
    England—~2156.9%71.6%76.7%
    Sources & context

    QOF achievement; GP Patient Survey, practice-level results

    Powered by Coplug · Page 9 of 15
    11 / 15

    What the data can't tell us: gaps and local assets

    What the data can't tell us: gaps and local assets

    Local assets and voluntary sectorPCNStockport (LAD)AssetPCNStockport (LAD)
    Care homes (catchment)26 (1,272 beds)n/aSchools (catchment)101n/a
    Children's centres22Places of worship44135
    Libraries312Food banks (VCS)n/a1
    Day centres (VCS)1no dataPrimary schools (LA maintained)2361
    Primary academies823Special schools34

    0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.

    Sources & context

    Gaps are modelled estimates against benchmark rates; local assets as supplied

    Powered by Coplug · Page 11 of 15
    12 / 15

    Options for the PCN

    Options for the PCN

    Each option in full

    Option 1

    Structured asthma annual review recall

    Asthma review coverage is 58.9% (England 65.7%, Stockport (LAD) 63.4%), falling 8.0% over 2023 to 2025 (England +4.4%), an estimated scale gap of 1,528 unreviewed patients across the 3,718 register. Moderate effort to run.

    Evidence base: the annual asthma review is the process gap between the register and outcomes.

    Policy anchor: Core20PLUS5 chronic respiratory disease priority.

    Option 2

    COPD case-finding and review recall

    COPD prevalence is 1.4% (810 patients; fell 4.7% over 2023 to 2025 vs England +2.6%), below England (1.9%) and Stockport (LAD) (2.1%), an unadjusted gap of +309 to +457 patients; reviews are 69.8% (England 76.4%). Moderate effort to run.

    Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.

    Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.

    Option 3

    High-risk lipid therapy and formulary review

    Lipid-lowering therapy for patients with QRISK ≥ 20% is 61.3% (3-year change +3.7%), below England (63.6%, +6.2%), Stockport (LAD) (64.8%), and ICB (67.0%); lipid-modifying items cost £2.50 vs England £1.86. Moderate effort to run.

    Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.

    Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).

    Sources & context

    Options are the profile's; evidence base from Coplug's indicator catalogue

    Powered by Coplug · Page 12 of 15
    13 / 15

    Provenance and audit trail

    Provenance and audit trail

    Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

    RecommendationIndicator(s)Policy anchorData level
    Older adult anticipatory care planning (p2)Aged 65+Neighbourhood health framework · NHS vaccination strategyPCN
    Targeted Core20 outreach (p3)Core20 cohort (IMD quintile 1)Core20PLUS5 · 10YHP equity testPCN
    SMI physical health review outreach (p4)SMI register with a BP check in the last 12 monthsMHIS · From Harm to HopePractice
    Hypertension case finding and review (p5)Hypertension: QOF prevalenceCore20PLUS5 CVD · CVDPREVENT 2029PCN
    Infant immunisation timing recall (p6)6-in-1 coverage at 12 months10YHP sickness to prevention · 95% targetPCN
    Targeted cervical screening recall (p7)Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs)Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026PCN
    Practice telephony and triage review (p9)GPPS easy to contact the practice by phone10YHP, hospital to communityPractice
    Option 1 · Structured asthma annual review recall (p12)Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs)Core20PLUS5 respiratoryPCN
    Option 2 · COPD case-finding and review recall (p12)COPD register · COPD: QOF prevalence · COPD patients with a review in the last 12 monthsCore20PLUS5 approach · Tobacco and Vapes BillPCN
    Option 3 · High-risk lipid therapy and formulary review (p12)Patients with QRISK ≥ 20% treated with lipid lowering therapy · Cost per item for Lipid-regulating drugs 2026 · Count of Items prescribed for Lipid-regulating drugs 2026Core20PLUS5 CVD · CVDPREVENT 2029PCN
    Sources & context

    Re-run this profile in 12 months to see whether the gaps have narrowed

    Powered by Coplug · Page 13 of 15
    14 / 15

    Data sources

    Data sources

    Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

    DatasetLevelPeriodUsed for
    Coplug indicator tables: census, deprivation and QOF measuresPCN & Practice2023 to 2025, projected to 2030; 2023 to 2024Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12
    MHCLG, Rough sleeping snapshot in England: autumn 2025Local authorityAutumn 2025Pages 2, 4
    OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713)PCN2024/25Pages 2, 4
    OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002)Local authority2024/25; 2022-24Pages 2, 4
    ONS, Census 2021 TS039: provision of unpaid care (age-standardised)Local authorityCensus 2021Pages 2, 4
    QOF registers, prevalence and care processes (Coplug indicator tables)Practice2023 to 2025, projected to 2030Pages 4, 5, 6, 7, 8, 10
    UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26PCN & PracticeQ1 2025/26Pages 4, 6
    UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026Local authority2025/26 season to 28 Feb 2026Pages 4, 6
    NHS England, Cancer Waiting Times: July 2026 monthly time series with revisionsICB & ProviderJul 2026 (provisional)Pages 7, 8
    NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental dataICB & Local authorityJun 2026 (provisional)Pages 7, 8
    NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026ProviderJul 2026Pages 7, 8
    National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022ICB2022Pages 7, 8
    NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted)PracticeSurvey Jan-Apr 2026Page 9
    NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domainPractice2025/26Page 9
    NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domainPractice2025/26Page 9
    Coplug indicator catalogue — definitions, cohorts, policy anchorsReferenceCurrentEvidence-base lines, page 13
    Sources & context

    Where a period is given as "as supplied", the source file did not state a vintage

    Powered by Coplug · Page 14 of 15
    15 / 15

    Methods, data-quality notes and limitations

    Methods, data-quality notes and limitations

    Methods

    Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.

    Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.

    Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.

    Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.

    Sources & context

    Estimates size the task; they are not confirmed missed patients

    Powered by Coplug · Page 15 of 15